-

09:19:05 AM

STSA Stock News

STSA - Satsuma Pharmaceuticals Inc

08/09/22 4:05 PM

Nasdaq : STSA

earningslow float

Satsuma Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Progress in STS101 Development Program

- Completed enrollment in the SUMMIT pivotal Phase 3 efficacy trial of STS101, randomizing more than 1,400 subjects - - On track to announce SUMMIT trial topline results in Q4 2022 - - Completed STS101 clinical and CMC pre-NDA meetings with FDA - - Presented nine abstracts at major medical meetings

RHEA-AI

neutral

08/02/22 8:00 AM

Nasdaq : STSA

clinical triallow float

Satsuma Pharmaceuticals Announces Completion of Enrollment in SUMMIT Pivotal Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101

RHEA-AI

neutral

06/09/22 7:00 AM

Nasdaq : STSA

low float

Satsuma Pharmaceuticals Announces Five Abstracts Accepted for Presentation at The American Headache Society’s 64th Annual Scientific Meeting

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine

RHEA-AI

neutral

06/07/22 4:05 PM

Nasdaq : STSA

low float

Satsuma Pharmaceuticals Hosting Key Opinion Leader Webinar on the Acute Treatment of Migraine, DHE, and STS101

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product

RHEA-AI

neutral

05/11/22 4:05 PM

Nasdaq : STSA

conferenceslow float

Satsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of

RHEA-AI

neutral

05/10/22 4:05 PM

Nasdaq : STSA

earningslow float

Satsuma Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights

- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing and on track to read out topline results in Q4 2022 - - New Drug Application (NDA) submission anticipated in Q1 2023 - - $80.6 million in cash, cash equivalents and marketable securities as of March 31, 2022, provides runway into second half

RHEA-AI

neutral

03/15/22 4:03 PM

Nasdaq : STSA

earningslow float

Satsuma Pharmaceuticals Reports 2021 Full Year and Fourth Quarter Financial Results and Business Highlights

- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing; key trial on track to read out topline results in Q4 2022 - - $95.8 million in cash, cash equivalents and marketable securities as of December 31, 2021, provides runway into second half of 2023 - SOUTH SAN FRANCISCO, Calif., March 15, 2022

RHEA-AI

positive

03/03/22 4:05 PM

Nasdaq : STSA

low float

Satsuma Pharmaceuticals Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2022 Annual Meeting

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of

RHEA-AI

neutral

02/08/22 8:30 AM

Nasdaq : STSA

conferenceslow float

Satsuma Pharmaceuticals to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of

RHEA-AI

neutral

11/09/21 4:05 PM

Nasdaq : STSA

earningslow float

Satsuma Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing, with topline results expected second half of 2022 - - Appointed Mutya Harsch to the Board of Directors – - $110 million in cash as of September 30, 2021 provides runway into second half of 2023 – SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021

RHEA-AI

very positive

STSA Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.satsumarx.com
CeoJohn Kollins
Security nameSatsuma Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees19
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address400 Oyster Point Blvd Ste 221
StateCalifornia
CitySouth San Francisco
Zip94080-1952
CountryUS
Phone14155050809

About Satsuma Pharmaceuticals Inc

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product candidate for the acute treatment of migraine. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. DHE products have long been recommended as a first-line therapeutic option for the acute treatment of migraine and have significant advantages over other therapeutics for many patients. However, broad use has been limited by invasive and burdensome administration and/or sub-optimal clinical performance of available injectable and liquid nasal spray products. STS101 is in Phase 3 development and specifically designed to deliver the clinical advantages of DHE while overcoming these shortcomings.